Abstract:We previously demonstrated significant therapeutic activities associated with adenoviral vector-mediated Herpes Simplex Virus/thymidine kinase (AdHSV-tk) with ganciclovir (GCV) in situ gene therapy in the RM-1 orthotopic mouse prostate cancer model and interleukin-12 (AdmIL-12) in situ gene therapy in the RM-9 orthotopic mouse prostate model for prostate cancer. In both protocols, local cytotoxicity and activities against pre-established lung metastases were demonstrated. To test whether combined AdHSV-tk+GCV+IL-12 gene therapy would lead to enhanced therapeutic effects when compared to either treatment alone, we used RM-9 mouse prostate cancer cells in both orthotopic and pre-established lung metastases models of prostate cancer. Combined treatment with a single injection of optimal doses of AdHSV-tk+GCV or AdmIL-12 led to significantly increased suppression of orthotopic tumor growth. IL-12 gene therapy alone was more effective than AdHSV-tk+GCV in suppressing spontaneous lymph node metastases and pre-established lung metastases but combination gene therapy did not result in additional anti-metastatic activities. Combination gene therapy also did not achieve significantly better animal survival compared to AdHSV-tk+GCV or AdmIL-12 alone. Analysis of localized antitumor activities demonstrated that AdHSV-tk+GCV therapy induced higher levels of necrosis compared to AdmIL-12 or combination therapy. However, both treatments alone and combination therapy produced similar increases in apoptotic index. To address the possible mechanisms of locally co-operative cytotoxic activities, we analyzed the systemic natural killer (NK) response and the numbers of tumor-infiltrating immune cells using quantitative immunohistochemical analysis. AdHSV-tk+GCV therapy alone led to detectable increases in iNOS-positive cells, CD4+and CD8+T-cells and moderately increased numbers of F4/80 (macrophage selective)-positive cells within treated tumors. In contrast, AdmIL-12 elicited a highly robust pattern of tumor infiltration for all four of these immune cells that was in general mimicked by combination therapy. Further analysis of the accumulation of transforming growth factor-β1 (TGF-β1) immunohistochemical staining demonstrated that AdHSV-tk+GCV treatment, but not AdmIL-12 treatment, produced cancer cell-associated increases in this cytokine relative to control Ad-β-gal injections. Interestingly, local injection with AdHSV-tk+GCV induced significant splenocyte-derived NK cell cytolytic activities with maximal response 7 days following treatment, whereas AdmIL-12 injection produced significantly higher NK activity with maximal response 2 days following injection. The combined treatment produced a higher systemic NK response over the 14-day treatment period. Depletion of NK cells in vivo demonstrated that this immunocyte subpopulation was responsible for early locally cytotoxic activities induced by AdHSV-tk+GCV but not AdmIL-12 and that NK activities were largely responsible for activities against pre-established metastases generated by both gene therapy protocols.

Retrovirus-mediated HSV1-tk Gene Therapy for Androgen-Independent Prostate Cancer

Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy for experimental prostate cancer

Gene Therapy with HSV1-sr39TK/GCV Exhibits a Stronger Therapeutic Efficacy Than HSV1-TK/GCV in Rat C6 Glioma Cells

Killing effect of mutant herpes simplex virus type 1 thymidine kinase on rat C6 glioma cells

Inhibitory effect of ultrasound microbubbles carrying HSV_1-TK gene combined with ganciclovir on prostate cancer cells

Hytk Gene Expression Promoted by PSA Promoters in Prostate Carcinoma Cell Lines

[Effects of herpes simplex virus thymidine kinase gene transduction and prodrug on ovarian cancer cell]

The Effects of HSV-TK/GCV Suicide Gene Therapy System on Human Pancreatic Cancer Cells

Rerovirus Mediated Hsv-Tk Gene Transfer Can Influence The Function Of Human T-Lymphocyte

Radiofrequency Hyperthermia-Enhanced Herpes Simplex Virus-Thymidine Kinase/ganciclovir Direct Intratumoral Gene Therapy of Hepatocellular Carcinoma

4:10 PM Abstract No. 50 Intratumoral Radiofrequency Hyperthermia-Enhanced Herpes Simplex Virus Thymidine Kinase (HSV-TK) Gene Therapy of Orthotopic Lung Cancer Through the Augmentation of Apoptosis and Heat Shock Protein (HSP70) Expression Pathway

Development of Provenge for Prostate Carcinoma Therapy

[Experimental Study on Human Pulmonary Adenocarcinoma Cell A549 Transfected with HSV₁-TK Gene in Vitro and in Vivo].

Experimental Study in Vitro on Gene Therapy for Prostate Cancer with Recombinant Adenoviral Vector Carrying LRIG1 Gene Driven by Survivin Promoter

UV Light-inactivated HSV-1 Stimulates Natural Killer Cell-induced Killing of Prostate Cancer Cells

Construction of the package cells( PA317/TK) with recombinant retroviral vector containing HSVtk gene

Anti-hepatoma effect of suicide gene therapy using HSV/TK combined with ganciclovir in hepatoma cells

PTEN and P27kip1 Have a Cooperative Role on Inhibition Proliferation,modulation of Cell Cycle and Inducing Apoptosis in Prostate Cancer PC-3 Cell

Combined Treatment of Cholangiocarcinoma with Interventional Radiofrequency Hyperthermia and Heat Shock Protein Promoter-Mediated HSV-TK Gene Therapy.

Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancer

TK Gene Combined with Mil-2 and Mgm-Csf Genes in Treatment of Gastric Cancer